Delaware
|
|
001-34637
|
|
20-1852016
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
25801 Industrial Boulevard, Suite B, Hayward,
California
|
|
94545
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01.
|
Other Events.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
Exhibit No.
|
|
Description
|
99.1
|
|
Date: August 28, 2017
|
|
|
Anthera Pharmaceuticals, Inc.
|
|||
|
|
By:
|
|
/s/ Craig Thompson
|
||
|
|
|
Craig Thompson
|
|||
|
|
|
President and Chief Executive Officer
(Principal Executive Officer)
|
Exhibit No.
|
|
Description
|
99.1
|
|